A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood - Trial NCT06419660
Access comprehensive clinical trial information for NCT06419660 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boehringer Ingelheim
Timeline & Enrollment
Phase 1
May 21, 2024
Jul 02, 2024
Primary Outcome
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz),Maximum measured concentration of the analyte in plasma (Cmax)
Summary
The main objective of this trial is to investigate the effect of the proton pump inhibitor
 esomeprazole on the pharmacokinetics of BI 3000202 in plasma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06419660
Non-Device Trial